• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Successful Treatment of NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARSCoV-2 Nosocomial Infection.头孢他啶/阿维巴坦联合氨曲南成功治疗血栓性血小板减少性紫癜合并新型冠状病毒医院感染患者的NDM败血症及肠道去定植
Medicina (Kaunas). 2021 Apr 28;57(5):424. doi: 10.3390/medicina57050424.
2
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
3
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.肺炎克雷伯菌对依拉环素耐药的产生及协同治疗策略的伴随敏感性指导设计。
Microbiol Spectr. 2022 Oct 26;10(5):e0139022. doi: 10.1128/spectrum.01390-22. Epub 2022 Aug 16.
4
Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.头孢他啶-阿维巴坦单药或与氨曲南联合多黏菌素治疗碳青霉烯类耐药肺炎克雷伯菌医院获得性感染(CAPRI 研究):来自印度南部的回顾性队列研究。
Infection. 2024 Apr;52(2):429-437. doi: 10.1007/s15010-023-02094-9. Epub 2023 Sep 11.
5
Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?替加环素联合头孢他啶-阿维巴坦治疗中性粒细胞减少症患者产 NDM-1 肺炎克雷伯菌菌血症:最后的治疗手段?
J Glob Antimicrob Resist. 2020 Dec;23:417-419. doi: 10.1016/j.jgar.2020.10.019. Epub 2020 Nov 16.
6
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.针对产 NDM-和 CTX-M 型肺炎克雷伯菌的细胞壁合成和外膜完整性的靶向治疗机制研究。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0052722. doi: 10.1128/aac.00527-22. Epub 2022 Aug 4.
7
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.波兰一家单中心对 23 例产新德里金属β-内酰胺酶(NDM)肺炎克雷伯菌感染患者使用头孢他啶/阿维巴坦和氨曲南治疗的结果。
Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.
8
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.监测头孢他啶-阿维巴坦和氨曲南在治疗一株携带肺炎克雷伯菌碳青霉烯酶 4 型和新德里金属β-内酰胺酶 1 型的多药耐药肠杆菌引起的血流感染中的浓度。
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
9
Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.使用雾化用氨曲南粉作为静脉治疗药物联合头孢他啶/阿维巴坦成功救治产新德里金属β-内酰胺酶(NDM)的泛耐药肺炎克雷伯菌所致败血症
J Antimicrob Chemother. 2020 Mar 1;75(3):773-775. doi: 10.1093/jac/dkz495.
10
Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Bacteremia: A Case Report.替加环素、头孢他啶/阿维巴坦和多黏菌素联合治疗产碳青霉烯酶菌血症:病例报告。
J Pharm Pract. 2021 Aug;34(4):653-657. doi: 10.1177/0897190019882262. Epub 2019 Nov 7.

引用本文的文献

1
Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections.头孢他啶阿维巴坦对碳青霉烯类耐药肠杆菌科细菌在相关感染治疗期间定植的影响。
Sci Rep. 2025 Aug 7;15(1):28935. doi: 10.1038/s41598-025-14817-z.
2
Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against by MALDI-TOF MS.通过基质辅助激光解吸电离飞行时间质谱法评估氨曲南和头孢他啶/阿维巴坦对……的协同作用
Antibiotics (Basel). 2023 Jun 16;12(6):1063. doi: 10.3390/antibiotics12061063.
3
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.耐碳青霉烯类:毒力因子、分子流行病学及治疗选择的最新进展
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
4
Successful treatment of ceftazidime/avibactam combined with aztreonam in the NDM-producing Klebsiella pneumoniae bloodstream and intestinal infections in a NK/T lymphoma patient with agranulocytosis during autologous hematopoietic stem cell transplantation: a case report.头孢他啶/阿维巴坦联合氨曲南成功治疗1例自体造血干细胞移植期间粒细胞缺乏的NK/T淋巴瘤患者血流感染及肠道感染产NDM肺炎克雷伯菌:病例报告
Eur J Clin Microbiol Infect Dis. 2022 Nov 12:1-4. doi: 10.1007/s10096-022-04523-3.
5
Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021).新冠病毒患者的抗菌药物耐药性:系统评价和荟萃分析(2019 年 11 月至 2021 年 6 月)。
Antimicrob Resist Infect Control. 2022 Mar 7;11(1):45. doi: 10.1186/s13756-022-01085-z.
6
Sepsis: New Challenges and Future Perspectives for an Evolving Disease-Precision Medicine Is the Way!脓毒症:一种不断演变的疾病面临的新挑战与未来展望——精准医学是方向!
Medicina (Kaunas). 2021 Oct 15;57(10):1109. doi: 10.3390/medicina57101109.
7
COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-binding proteins, platelet factor 4, prothrombin, and coagulation factors.COVID-19 凝血功能障碍:人类血液蛋白模拟 SARS-CoV-2 病毒、疫苗蛋白和细菌合并感染诱导自身免疫:细菌和 SARS-CoV-2 的组合协同诱导针对心磷脂、心磷脂结合蛋白、血小板因子 4、凝血酶原和凝血因子的自身抗体。
Bioessays. 2021 Dec;43(12):e2100158. doi: 10.1002/bies.202100158. Epub 2021 Oct 22.
8
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.氨曲南与阿维巴坦联合用于治疗产金属β-内酰胺酶革兰阴性菌的研究进展:体外研究与临床病例的系统评价
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.

本文引用的文献

1
COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network.COVID-19 增加了 ICU 获得性血流感染的风险:来自多中心 OUTCOMEREA 网络的病例队列研究。
Intensive Care Med. 2021 Feb;47(2):180-187. doi: 10.1007/s00134-021-06346-w. Epub 2021 Jan 27.
2
Extremely drug-resistant NDM-9-producing ST147 causing infections in Italy, May 2020.2020 年 5 月,意大利出现了携带 NDM-9 超级耐药基因的 ST147 型超级细菌,引发感染。
Euro Surveill. 2020 Dec;25(48). doi: 10.2807/1560-7917.ES.2020.25.48.2001779.
3
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
4
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响:一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
5
Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis.肠道通透性的改变伴随着细菌易位,是调节机体对 SARS-CoV-2 全身免疫反应的关键事件:一个工作假说。
Dig Liver Dis. 2020 Dec;52(12):1383-1389. doi: 10.1016/j.dld.2020.09.009. Epub 2020 Sep 16.
6
Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.新型冠状病毒肺炎患者的凝血病、静脉血栓栓塞和抗凝治疗。
Pharmacotherapy. 2020 Nov;40(11):1130-1151. doi: 10.1002/phar.2465. Epub 2020 Nov 3.
7
Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 的疗效:系统评价和荟萃分析。
J Med Virol. 2021 Mar;93(3):1620-1630. doi: 10.1002/jmv.26509. Epub 2020 Sep 28.
8
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.头孢他啶-阿维巴坦联合氨曲南治疗产金属β-内酰胺酶肠杆菌科血流感染的疗效。
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878. doi: 10.1093/cid/ciaa586.
9
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
10
Hematological findings and complications of COVID-19.COVID-19 的血液学表现及并发症。
Am J Hematol. 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829. Epub 2020 May 23.

头孢他啶/阿维巴坦联合氨曲南成功治疗血栓性血小板减少性紫癜合并新型冠状病毒医院感染患者的NDM败血症及肠道去定植

Successful Treatment of NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARSCoV-2 Nosocomial Infection.

作者信息

Perrotta Francesco, Perrini Marco Paolo

机构信息

Department of Anesthesia and Intensive Care Unit, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini, 1, 71013 San Giovanni Rotondo, FG, Italy.

Department of Anesthesia and Intensive Care Unit, Università degli Studi di Foggia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, 1, 71122 Viale Pinto, FG, Italy.

出版信息

Medicina (Kaunas). 2021 Apr 28;57(5):424. doi: 10.3390/medicina57050424.

DOI:10.3390/medicina57050424
PMID:33924769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8145860/
Abstract

Carbapenem-resistant (CRE) are a serious public health threat. Infections due to these organisms are associated with significant morbidity and mortality. Among them, metallo-β-lactamases (MBLs)-producing are of global concern today. The ceftazidime/avibactam combination and the ceftazidime/avibactam + aztreonam combination currently represent the most promising antibiotic strategies to stave off these kinds of infections. We describe the case of a patient affected by thrombotic thrombocytopenic purpura (TTP) admitted in our ICU after developing a hospital-acquired SarsCoV2 interstitial pneumonia during his stay in the hematology department. His medical conditions during his ICU stay were further complicated by a NDM sepsis. To our knowledge, the patient had no risk factors for multidrug-resistant bacteria exposure or contamination during his stay in the hematology department. During his stay in the ICU, we treated the sepsis with a combination therapy of ceftazidime/avibactam + aztreonam. The therapy solved his septic state, allowing for a progressive improvement in his general condition. Moreover, we noticed that the negativization of the hemocultures was also associated to a decontamination of his known rectal colonization. The ceftazidime/avibactam + aztreonam treatment could not only be a valid therapeutic option for these kinds of infections, but it could also be considered as a useful tool in selected patients' intestinal decolonizations.

摘要

耐碳青霉烯类肠杆菌科细菌(CRE)是严重的公共卫生威胁。这些病原体引起的感染与显著的发病率和死亡率相关。其中,产金属β-内酰胺酶(MBL)的细菌目前受到全球关注。头孢他啶/阿维巴坦联合用药以及头孢他啶/阿维巴坦+氨曲南联合用药目前是抵御这类感染最有前景的抗生素策略。我们描述了一例血栓性血小板减少性紫癜(TTP)患者的病例,该患者在血液科住院期间发生医院获得性新型冠状病毒2型间质性肺炎后入住我们的重症监护病房(ICU)。他在ICU住院期间的病情因新德里金属β-内酰胺酶(NDM)败血症而进一步复杂化。据我们所知,该患者在血液科住院期间没有接触或感染多重耐药菌的风险因素。在他入住ICU期间,我们用头孢他啶/阿维巴坦+氨曲南联合疗法治疗败血症。该疗法解决了他的败血症状态,使他的总体状况逐渐改善。此外,我们注意到血培养转阴也与他已知的直肠定植菌清除有关。头孢他啶/阿维巴坦+氨曲南治疗不仅可能是这类感染的有效治疗选择,而且在选定患者的肠道去定植方面也可被视为一种有用的工具。